National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 81923 [2024-23323]

Download as PDF Federal Register / Vol. 89, No. 196 / Wednesday, October 9, 2024 / Notices Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: October 3, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. National Institutes of Health [FR Doc. 2024–23322 Filed 10–8–24; 8:45 am] Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting khammond on DSKJM1Z7X2PROD with NOTICES Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). Date: November 7, 2024. Time: 2:00 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20892 (Video Assisted Meeting). Contact Person: Tara Capece, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 20892, 240–191–4281, capecet2@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: October 3, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–23323 Filed 10–8–24; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 17:05 Oct 08, 2024 Jkt 265001 Center for Scientific Review; Notice of Closed Meetings Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowship: NIH Medical Scientist Partnership Program (FM1). Date: October 31-November 1, 2024. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Raj K Krishnaraju, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6190, MSC 7804, Bethesda, MD 20892, (301) 435– 1047, kkrishna@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Special Topics in Clinical Neuroscience. Date: November 4, 2024. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Boris P Sokolov, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217A, MSC 7846, Bethesda, MD 20892, 301–408– 9115, bsokolov@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 23– 077: Collaborative Program Grant for Multidisciplinary Teams (RM1). Date: November 4, 2024. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sergei Ruvinov, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4158, PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 81923 MSC 7806, Bethesda, MD 20892, 301–435– 1180, ruvinser@csr.nih.gov. Name of Committee: Applied Immunology and Disease Control Integrated Review Group; Drug Discovery and Molecular Pharmacology A Study Section. Date: November 5–6, 2024. Time: 8:30 a.m. to 8:30 p.m. Agenda: To review and evaluate grant applications. Address: DoubleTree by Hilton McLean Tysons, 1960 Chain Bridge Rd., McLean, VA 22102. Contact Person: Bidyottam Mittra, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, Bethesda, MD 20892, (301) 435–0000, bidyottam.mittra@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Cell Biology, Developmental Biology, and Bioengineering. Date: November 5–6, 2024. Time: 9:30 a.m. to 7:30 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Alexander Gubin, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4196, MSC 7812, Bethesda, MD 20892, 301–435– 2902, gubina@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Infectious Disease Drug Development and Molecular Pharmacology. Date: November 5–6, 2024. Time: 10:00 a.m. to 8:30 p.m. Agenda: To review and evaluate grant applications. Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Ekaterina Mikhailovna Nestorovich, Scientific Review Officer, The Center for Scientific Review, The National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 827–1367, ekaterina.nestorovich@nih.gov. Name of Committee: Applied Immunology and Disease Control Integrated Review Group; Anti-Infective Resistance and Targets Study Section. Date: November 6–7, 2024. Time: 8:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Address: Embassy Suites Alexandria Old Town, 1900 Diagonal Road, Alexandria, VA 22314. Contact Person: Jui Pandhare, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–7735, pandharej2@ csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Neuroimmune and Neuroinflammation involved in Neurodegenerative Disorders. Date: November 6–7, 2024. Time: 8:00 a.m. to 6:30 p.m. E:\FR\FM\09OCN1.SGM 09OCN1

Agencies

[Federal Register Volume 89, Number 196 (Wednesday, October 9, 2024)]
[Notices]
[Page 81923]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-23323]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial 
Implementation Cooperative Agreement (U44 Clinical Trial Required).
    Date: November 7, 2024.
    Time: 2:00 p.m. to 3:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G41, 
Rockville, MD 20892 (Video Assisted Meeting).
    Contact Person: Tara Capece, Ph.D., Scientific Review Officer, 
Scientific Review Program, Division of Extramural Activities, 
National Institute of Allergy and Infectious Diseases, National 
Institutes of Health, 5601 Fishers Lane, Room 3G41, Rockville, MD 
20892, 240-191-4281, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856, 
Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: October 3, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-23323 Filed 10-8-24; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.